The approval allows Genzyme to begin returning patients to full doses of Fabrazyme. By March, patients in the U.S. will be returned to full dosing. Normal supply levels are expected by the second quarter.
Related Articles on the Supply Chain:
FDA Clears Medtronic’s Aquamantys SBS 5.0 Sheathed Bipolar Sealer for Spine Surgery
MScore Technology Assesses Surgeon Competency With da Vinci Robot
FDA, Life Sciences Trade Group Partner to Improve Medical Device Review
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.